Latest news with #Stranahan
Business Insider
14-06-2025
- Business
- Business Insider
Bank of America Securities Sticks to Its Buy Rating for RegenXBio (RGNX)
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $22.00. The company's shares opened today at $9.72. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Stranahan covers the Healthcare sector, focusing on stocks such as Novavax, RegenXBio, and Candel Therapeutics. According to TipRanks, Stranahan has an average return of -9.6% and a 39.81% success rate on recommended stocks. RegenXBio has an analyst consensus of Strong Buy, with a price target consensus of $31.27, a 221.71% upside from current levels. In a report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $40.00 price target. Based on RegenXBio's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $89.01 million and a net profit of $6.08 million. In comparison, last year the company earned a revenue of $15.62 million and had a GAAP net loss of $63.33 million
Business Insider
01-06-2025
- Business
- Business Insider
Bank of America Securities Remains a Buy on Revolution Medicines (RVMD)
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Revolution Medicines (RVMD – Research Report) on May 30 and set a price target of $78.00. Confident Investing Starts Here: Stranahan covers the Healthcare sector, focusing on stocks such as Novavax, Y-Mabs Therapeutics, and TG Therapeutics. According to TipRanks, Stranahan has an average return of -11.2% and a 35.35% success rate on recommended stocks. Currently, the analyst consensus on Revolution Medicines is a Strong Buy with an average price target of $70.63.
Yahoo
21-05-2025
- Business
- Yahoo
BofA Reiterates Hold Rating on Novavax (NVAX) Stock
On May 20, BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of 2025. Stranahan cited that this will mitigate near-term risks. However, the analyst pointed out that the post-marketing commitments and the need for further trials are already considered in Novavax's guidance, indicating minimal influence on the stock's performance. A person holding a syringe filled with a vaccine, implying the companys impact on health and wellbeing. As the demand for COVID vaccines remains sizeable among older populations, the stricter labeling may not have a drastic impact on Nuvaxovid's potential market. Overall, the analyst maintains a neutral view on the stock, considering the full potential of Novavax's pipeline remains to be unlocked. Novavax, Inc. (NASDAQ:NVAX) is a biotechnology firm that is engaged in the discovery, development, and commercialization of vaccines to protect against serious diseases worldwide. While we acknowledge the potential of NVAX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVAX and that has 100x upside potential, check out our report about this cheapest AI stock. Read Next: and . Disclosure. None. Sign in to access your portfolio
Business Insider
15-05-2025
- Business
- Business Insider
Bank of America Securities Remains a Buy on Beam Therapeutics (BEAM)
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) yesterday and set a price target of $43.00. The company's shares closed yesterday at $17.24. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Stranahan is an analyst with an average return of -12.1% and a 34.60% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Beam Therapeutics, Candel Therapeutics, and Novavax. In addition to Bank of America Securities, Beam Therapeutics also received a Buy from JonesTrading's Soumit Roy in a report issued on May 8. However, on May 7, Barclays maintained a Hold rating on Beam Therapeutics (NASDAQ: BEAM).
Forbes
15-05-2025
- General
- Forbes
This Brewer's Cask Single Malt Doesn't Let Beer Overpower The Whiskey
Stranahan's Diamond Peak Brewer's Cask Colorado-based Stranahan's celebrated their 20th anniversary in 2024, and today, the Denver distillery is one of the oldest producers of American Single Malt. (A category of spirit that was recognized by the federal government this past January.) While the distillery is known for a wide variety of specialty releases and cask finishes, one of its latest bottles pays homage to its origins and Colorado's storied brewing culture. Fortunately for whiskey drinkers, this is one collaboration where the beer enhances the drinking experience instead of overpowering it. All Stranahan's single malt initially ages in new charred American oak barrels. After an initial aging period, often between four and six years, some of that whiskey is transferred to a variety of other casks for extended finishing. As someone who has seen their operation up close, the distillery's deep stocks feature a dizzying array of finishing casks, including barrels that previously held a broad diversity of wines, as well as spirits including mezcal, rum, peated Scotch, and more. To focus in on a single type of secondary barrel aging, Diamond Peak is Stranahan's annual, nationwide bottling that highlights 'one specific variety of speciality cask-finished whiskies.' The 2025 version of Diamond Peak—the fourth edition overall—is titled 'Local Brewer's Cask.' To create the expression, Stranahan's lent their used American single malt casks to four Denver-area breweries. Local beer was aged in those barrels, after which they were dumped and returned to Stranahan's (or 'boomeranged' according an evocatively worded press release). Those barrels were then refilled with Stranahan's single malt, which aged for an additional period of between one and one-and-a-half years, depending on the barrel. The liquid in those final barrels was blended to create this year's Diamond Peak release. Previous versions of Diamond Peak featured whiskey that underwent additional aging in casks that once held Bushmills, extra añejo tequila, and Caribbean rum. (Bushmills and Stranahan's are both owned by Proximo Spirits.) But this latest, beer-influenced Diamond Peak gets extra points due to the nostalgia factor. In fact, the first version of what would become Stranahan's single malt was distilled from beer mash made by Colorado's Flying Dog Brewery. Stranahan's has long maintained relationships and collaborated with local breweries on a variety of projects. But the proof is ultimately in the taste. So how does this latest Diamond Peak stack up? The nose starts off with some classic scents familiar to longtime Stranahan's drinkers: dried orange peel, candied ginger, rum raisin ice cream, fresh drip coffee, and heavily spiced fruitcake. At least based on aroma, it's a little funkier and more intensely spiced than some other recent expressions from the distillery—but it's certainly not overpoweringly hoppy or otherwise tilted more toward beer than the base whiskey. (A trough some beer barrel-finished American whiskeys can easily fall into, for better or for worse.) The palate leads with some light tropical fruit—fresh pineapple, ripe papaya—with some tannins in the realm of cigar box and fermented tea leaves. Birch and cedar build mildly at the midpalate, along with mulberries and a touch of hard apple cider. The flavor is quite pronounced for 90 proof (frankly a bit more than I was expecting), which leads to a balanced finish that once again leans into a variety of fruits with enough oak to cut through the sweetness. This latest iteration of Stranahan's Diamond Peak is now available at the distillery for $79.99 and at select retailers (where prices may vary).
